Actiphage is the first diagnostic for tuberculosis that can detect live mycobacteria in a sample of blood or milk.
Actiphage is non-sputum based diagnostic that can detect disease progression.
To be the global leader in novel phage-based diagnostics for the diagnosis of tuberculosis.
To support the scale-up of test-and-treat campaigns for latent tuberculosis (LTI) to realise the goals of the WHO ‘End TB strategy’
Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom
Actiphage only test for subclinical tuberculosis that detects mycobacteria in blood @TAGTeam_Tweets Pipeline Report 2022 reveals of the 10.6m people who developed active TB last year, only 6.4m were diagnosed. A vast unmet need #endTB
Read MoreNew Pipeline report @TAGTeam_Tweets says investment in R&D for TB diagnostics R&D reached an all time high in 2020. Interesting description of 'acoustic epidemiology' AI-based tools that detect and monitor cough & lung sounds as biomarker for TB #EndTB
Read MoreVery useful explanation of latent TB infection from @CDC_TB and importance of preventative treatment. #EndTB
Read More
